echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Toripalimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer

    J Clin Oncol: Toripalimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Toripalimab is a specific human-derived IgG4K monoclonal antibody against human PD-1 that has a different domain


    The CHOICE-01 study evaluated the efficacy and safety


    465 patients with advanced NSCLC who did not carry the EGFR/ALK mutation were randomly divided into two groups and received 4 to 6 courses of chemotherapy with Toripalimab (240 mg, n=309) or placebo (1 beat/3 weeks) plus chemotherapy, followed by Toripalimab or placebo with standard of care maintenance



    At the time of the final PFS analysis, PFS was significantly longer in the Toripalimab group than in the placebo group (median PFS: 8.



    The incidence of grade 3 and above adverse reactions was similar


    Together, the findings show that Toripalimab combined chemotherapy significantly improves PFS and OS in patients with untreated advanced NSCLC with controlled safety


    Original Source:

    Zhijie Wang, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.